Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether KAI-1678 is effective in the treatment of postherpetic neuralgia pain

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: KAI Pharmaceuticals
• Collaborator: Trident Clinical Research Pty Ltd
• Treatments: Lidocaine

Criteria

Inclusion Criteria:

• diagnosis of PHN with pain for at least 3 months after segmental herpes zoster eruption

• pain score at least 4 on 11-point numerical rating scale (0-10)

• stable doses of analgesic medications for at least 1 month"

Exclusion Criteria:

• diagnosis of PHN with pain for at least 3 months after segmental herpes zoster eruption

• pain score at least 4 on 11-point numerical rating scale (0-10)

• stable doses of analgesic medications for at least 1 month"